• Published On : Jul-2017 |
  • Pages : 215 Pages |
  • Format :

Table of Content

1. Executive Summary
   1.1. Market Overview
   1.2. Market Analysis
   1.3. Wheel of Fortune

2. Market Introduction
   2.1. Market Definition
   2.2. Market Taxonomy
   2.3. Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Overview

3. Market View Point
   3.1. Macro-Economic Factors
   3.2. Opportunities
   3.3. Forecast Factors: Relevance and Impact
   3.4. Reimbursement Scenario
   3.5. Regulatory Scenario
   3.6. Pipeline Analysis

4. North America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Analysis 2012–2016 and Forecast 2017–2025
   4.1. Introduction
   4.2. Regional Market Dynamics
        4.2.1. Drivers
        4.2.2. Restraints
        4.2.3. Trends
   4.3. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016
        4.3.1. U.S.
        4.3.2. Canada
   4.4. Market Size (US$ Mn) and Forecast By Country, 2017–2025
        4.4.1. U.S.
        4.4.2. Canada
   4.5. Historical Market Size (US$ Mn) Analysis By Treatment Type, 2012–2016
        4.5.1. Chemotherapy
               4.5.1.1. Gemcitabine Combination Therapy
               4.5.1.2. 5-fluorouracil Combination Therapy
               4.5.1.3. Capecitabine Combination Therapy
               4.5.1.4. Gemcitabine Single Agent
   4.6. Market Size (US$ Mn) Forecast By Treatment Type, 2017–2025
        4.6.1. Chemotherapy
               4.6.1.1. Gemcitabine Combination Therapy
               4.6.1.2. 5-fluorouracil Combination Therapy
               4.6.1.3. Capecitabine Combination Therapy
               4.6.1.4. Gemcitabine Single Agent
   4.7. Historical Market Size (US$ Mn) Analysis By Disease Indication, 2012–2016
        4.7.1. Intrahepatic Bile Duct Cancer
        4.7.2. Extrahepatic Bile Duct Cancer
               4.7.2.1. Perihilar Bile Duct Cancer
               4.7.2.2. Distal Extrahepatic Bile Duct Cancer
   4.8. Market Size (US$ Mn) Forecast By Disease Indication, 2017–2025
        4.8.1. Intrahepatic Bile Duct Cancer
        4.8.2. Extrahepatic Bile Duct Cancer
               4.8.2.1. Perihilar Bile Duct Cancer
               4.8.2.2. Distal Extrahepatic Bile Duct Cancer
   4.9. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012–2016
        4.9.1. Hospital Pharmacies
        4.9.2. Retail Pharmacies
        4.9.3. Online Pharmacies
   4.10. Market Size (US$ Mn) and Forecast, By Distribution Channel, 2017–2025
        4.10.1. Hospital Pharmacies
        4.10.2. Retail Pharmacies
        4.10.3. Online Pharmacies
   4.11. Market Attractiveness Analysis
        4.11.1. By Country
        4.11.2. By Treatment Type
        4.11.3. By Disease Indication
        4.11.4. By Distribution Channel

5. Latin America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Analysis and Forecast, 2015-2015, By Products 
   5.1. Introduction
   5.2. Regional Market Dynamics
        5.2.1. Drivers
        5.2.2. Restraints
        5.2.3. Trends
   5.3. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016
        5.3.1. Brazil
        5.3.2. Mexico
        5.3.3. Rest of Latin America
   5.4. Market Size (US$ Mn) and Forecast By Country, 2017–2025
        5.4.1. Brazil
        5.4.2. Mexico
        5.4.3. Rest of Latin America 
   5.5. Historical Market Size (US$ Mn) Analysis By Treatment Type, 2012–2016
        5.5.1. Chemotherapy
               5.5.1.1. Gemcitabine Combination Therapy
               5.5.1.2. 5-fluorouracil Combination Therapy
               5.5.1.3. Capecitabine Combination Therapy
               5.5.1.4. Gemcitabine Single Agent
   5.6. Market Size (US$ Mn) Forecast By Treatment Type, 2017–2025
        5.6.1. Chemotherapy
               5.6.1.1. Gemcitabine Combination Therapy
               5.6.1.2. 5-fluorouracil Combination Therapy
               5.6.1.3. Capecitabine Combination Therapy
               5.6.1.4. Gemcitabine Single Agent
   5.7. Historical Market Size (US$ Mn) Analysis By Disease Indication, 2012–2016
        5.7.1. Intrahepatic Bile Duct Cancer
        5.7.2. Extrahepatic Bile Duct Cancer
               5.7.2.1. Perihilar Bile Duct Cancer
               5.7.2.2. Distal Extrahepatic Bile Duct Cancer
   5.8. Market Size (US$ Mn) Forecast By Disease Indication, 2017–2025
        5.8.1. Intrahepatic Bile Duct Cancer
        5.8.2. Extrahepatic Bile Duct Cancer
               5.8.2.1. Perihilar Bile Duct Cancer
               5.8.2.2. Distal Extrahepatic Bile Duct Cancer
   5.9. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012–2016
        5.9.1. Hospital Pharmacies
        5.9.2. Retail Pharmacies
        5.9.3. Online Pharmacies
   5.10. Market Size (US$ Mn) and Forecast, By Distribution Channel, 2017–2025
        5.10.1. Hospital Pharmacies
        5.10.2. Retail Pharmacies
        5.10.3. Online Pharmacies

6. Europe Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Analysis and Forecast
   6.1. Introduction
   6.2. Regional Market Dynamics
        6.2.1. Drivers
        6.2.2. Restraints
        6.2.3. Trends
   6.3. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016
        6.3.1. Germany
        6.3.2. France
        6.3.3. U.K.
        6.3.4. Spain
        6.3.5. Italy
        6.3.6. BENELUX
        6.3.7. Russia
        6.3.8. Rest of Europe
   6.4. Market Size (US$ Mn) and Forecast By Country, 2017–2025
        6.4.1. Germany
        6.4.2. France
        6.4.3. U.K.
        6.4.4. Spain
        6.4.5. Italy
        6.4.6. BENELUX
        6.4.7. Poland
        6.4.8. Russia
        6.4.9. Rest of Europe
   6.5. Historical Market Size (US$ Mn) Analysis By Treatment Type, 2012–2016
        6.5.1. Chemotherapy
               6.5.1.1. Gemcitabine Combination Therapy
               6.5.1.2. 5-fluorouracil Combination Therapy
               6.5.1.3. Capecitabine Combination Therapy               
               6.5.1.4. Gemcitabine Single Agent
   6.6. Market Size (US$ Mn) Forecast By Treatment Type, 2017–2025
        6.6.1. Chemotherapy
               6.6.1.1. Gemcitabine Combination Therapy
               6.6.1.2. 5-fluorouracil Combination Therapy
               6.6.1.3. Capecitabine Combination Therapy
               6.6.1.4. Gemcitabine Single Agent
   6.7. Historical Market Size (US$ Mn) Analysis By Disease Indication, 2012–2016
        6.7.1. Intrahepatic Bile Duct Cancer
        6.7.2. Extrahepatic Bile Duct Cancer
               6.7.2.1. Perihilar Bile Duct Cancer
               6.7.2.2. Distal Extrahepatic Bile Duct Cancer
   6.8. Market Size (US$ Mn) Forecast By Disease Indication, 2017–2025
        6.8.1. Intrahepatic Bile Duct Cancer
        6.8.2. Extrahepatic Bile Duct Cancer
               6.8.2.1. Perihilar Bile Duct Cancer
               6.8.2.2. Distal Extrahepatic Bile Duct Cancer
   6.9. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012–2016
        6.9.1. Hospital Pharmacies
        6.9.2. Retail Pharmacies
        6.9.3. Online Pharmacies
   6.10. Market Size (US$ Mn) and Forecast, By Distribution Channel, 2017–2025
        6.10.1. Hospital Pharmacies
        6.10.2. Retail Pharmacies
        6.10.3. Online Pharmacies

7. Asia Pacific Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Analysis and Forecast
   7.1. Introduction
   7.2. Regional Market Dynamics
        7.2.1. Drivers
        7.2.2. Restraints
        7.2.3. Trends
   7.3. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016
        7.3.1. China
        7.3.2. India
        7.3.3. Australia and New Zealand
        7.3.4. ASEAN
        7.3.5. Rest of ASIA PACIFIC
   7.4. Market Size (US$ Mn) and Forecast By Country, 2017–2025
        7.4.1. China
        7.4.2. India
        7.4.3. Australia and New Zealand
        7.4.4. ASEAN
        7.4.5. Rest of Asia Pacific
   7.5. Historical Market Size (US$ Mn) Analysis By Treatment Type, 2012–2016
        7.5.1. Chemotherapy
               7.5.1.1. Gemcitabine Combination Therapy
               7.5.1.2. 5-fluorouracil Combination Therapy
               7.5.1.3. Capecitabine Combination Therapy
               7.5.1.4. Gemcitabine Single Agent
   7.6. Market Size (US$ Mn) Forecast By Treatment Type, 2017–2025
        7.6.1. Chemotherapy
               7.6.1.1. Gemcitabine Combination Therapy
               7.6.1.2. 5-fluorouracil Combination Therapy
               7.6.1.3. Capecitabine Combination Therapy
               7.6.1.4. Gemcitabine Single Agent
   7.7. Historical Market Size (US$ Mn) Analysis By Disease Indication, 2012–2016
        7.7.1. Intrahepatic Bile Duct Cancer
        7.7.2. Extrahepatic Bile Duct Cancer
               7.7.2.1. Perihilar Bile Duct Cancer
               7.7.2.2. Distal Extrahepatic Bile Duct Cancer
   7.8. Market Size (US$ Mn) Forecast By Disease Indication, 2017–2025
        7.8.1. Intrahepatic Bile Duct Cancer
        7.8.2. Extrahepatic Bile Duct Cancer
               7.8.2.1. Perihilar Bile Duct Cancer
               7.8.2.2. Distal Extrahepatic Bile Duct Cancer
   7.9. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012–2016
        7.9.1. Hospital Pharmacies
        7.9.2. Retail Pharmacies
        7.9.3. Online Pharmacies
   7.10. Market Size (US$ Mn) and Forecast, By Distribution Channel, 2017–2025
        7.10.1. Hospital Pharmacies
        7.10.2. Retail Pharmacies
        7.10.3. Online Pharmacies

8. MEA Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Analysis and Forecast
   8.1. Introduction
   8.2. Regional Market Dynamics
        8.2.1. Drivers
        8.2.2. Restraints
        8.2.3. Trends
   8.3. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016
        8.3.1. GCC Countries
        8.3.2. South Africa
        8.3.3. Rest of MEA
   8.4. Market Size (US$ Mn) and Forecast By Country, 2017–20
        8.4.1. GCC Countries
        8.4.2. South Africa
        8.4.3. Rest of MEA
   8.5. Historical Market Size (US$ Mn) Analysis By Treatment Type, 2012–2016
        8.5.1. Chemotherapy
               8.5.1.1. Gemcitabine Combination Therapy
               8.5.1.2. 5-fluorouracil Combination Therapy
               8.5.1.3. Capecitabine Combination Therapy
               8.5.1.4. Gemcitabine Single Agent
   8.6. Market Size (US$ Mn) Forecast By Treatment Type, 2017–2025
        8.6.1. Chemotherapy
               8.6.1.1. Gemcitabine Combination Therapy
               8.6.1.2. 5-fluorouracil Combination Therapy
               8.6.1.3. Capecitabine Combination Therapy
               8.6.1.4. Gemcitabine Single Agent
   8.7. Historical Market Size (US$ Mn) Analysis By Disease Indication, 2012–2016
        8.7.1. Intrahepatic Bile Duct Cancer
        8.7.2. Extrahepatic Bile Duct Cancer
               8.7.2.1. Perihilar Bile Duct Cancer
               8.7.2.2. Distal Extrahepatic Bile Duct Cancer
   8.8. Market Size (US$ Mn) Forecast By Disease Indication, 2017–2025
        8.8.1. Intrahepatic Bile Duct Cancer
        8.8.2. Extrahepatic Bile Duct Cancer
               8.8.2.1. Perihilar Bile Duct Cancer
               8.8.2.2. Distal Extrahepatic Bile Duct Cancer
   8.9. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012–2016
        8.9.1. Hospital Pharmacies
        8.9.2. Retail Pharmacies
        8.9.3. Online Pharmacies
   8.10. Market Size (US$ Mn) and Forecast, By Distribution Channel, 2017–2025
        8.10.1. Hospital Pharmacies
        8.10.2. Retail Pharmacies
        8.10.3. Online Pharmacies

9. Competition Landscape
   9.1. Competition Dashboard
   9.2. Company Profiles (Details – Overview, Financials, Strategy, Recent Developments)
        9.2.1. Pfizer, Inc.
        9.2.2. F. Hoffman-La Roche AG
        9.2.3. Bristol-Myers Squibb Company
        9.2.4. Teva Pharmaceuticals Industries Ltd.
        9.2.5. Eli Lilly and Company
        9.2.6. Novartis AG
        9.2.7. Sanofi
        9.2.8. Fresenius Kabi AG
        9.2.9. Mylan N.V.
        9.2.10. Kyowa Hakko Kirin Co Ltd.
        9.2.11. Intercept Pharmaceuticals, Inc.
        9.2.12. Accord Healthcare Inc.
        9.2.13. Delcath Systems Inc.
        9.2.14. Celgene Corporation
        9.2.15. Johnson & Johnson

10. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Analysis 2012–2016 and Forecast 2017–2025, By Region
   10.1. Introduction / Key Findings
   10.2. Historical Market Size (US$ Mn) Analysis By Region, 2012-2016
        10.2.1. North America
        10.2.2. Latin America
        10.2.3. Europe
        10.2.4. Asia Pacific
        10.2.5. MEA
   10.3. Market Size (US$ Mn) Forecast By Region, 2017-2025
        10.3.1. North America
        10.3.2. Latin America
        10.3.3. Europe
        10.3.4. Asia Pacific
        10.3.5. MEA
   10.4. Market Attractiveness Analysis By Region

11. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Analysis 2012–2016 and Forecast 2017–2025, By Treatment Type
   11.1. Introduction
   11.2. Historical Market Size (US$ Mn) Analysis By Treatment Type, 2012–2016
        11.2.1. Chemotherapy
               11.2.1.1. Gemcitabine Combination Therapy
               11.2.1.2. 5-fluorouracil Combination Therapy
               11.2.1.3. Capecitabine Combination Therapy
               11.2.1.4. Gemcitabine Single Agent
   11.3. Market Size (US$ Mn) Forecast By Treatment Type, 2017–2025
        11.3.1. Chemotherapy
               11.3.1.1. Gemcitabine Combination Therapy
               11.3.1.2. 5-fluorouracil Combination Therapy
               11.3.1.3. Capecitabine Combination Therapy
               11.3.1.4. Gemcitabine Single Agent
   11.4. Market Attractiveness Analysis By Treatment Type

12. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Analysis 2012–2016 and Forecast 2017–2025, By Disease Indication
   12.1. Introduction
   12.2. Historical Market Size (US$ Mn) Analysis By Disease Indication, 2012–2016
        12.2.1. Intrahepatic Bile Duct Cancer
        12.2.2. Extrahepatic Bile Duct Cancer
               12.2.2.1. Perihilar Bile Duct Cancer
               12.2.2.2. Distal Extrahepatic Bile Duct Cancer
   12.3. Market Size (US$ Mn) Forecast By Disease Indication, 2017–2025
        12.3.1. Intrahepatic Bile Duct Cancer
        12.3.2. Extrahepatic Bile Duct Cancer
               12.3.2.1. Perihilar Bile Duct Cancer
               12.3.2.2. Distal Extrahepatic Bile Duct Cancer
   12.4. Market Attractiveness Analysis By Disease Indication

13. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Analysis 2012–2016 and Forecast 2017–2025, By Distribution Channel
   13.1. Introduction
   13.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012-2016
        13.2.1. Hospital Pharmacies
        13.2.2. Retail Pharmacies
        13.2.3. Online Pharmacies
   13.3. Market Size (US$ Mn) and Forecast By Distribution Channel, 2017-2025
        13.3.1. Hospital Pharmacies
        13.3.2. Retail Pharmacies
        13.3.3. Online Pharmacies
   13.4. Market Attractive Analysis By Distribution Channel

14.  Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Analysis, By Services Spending
   14.1. Historical Market Size (US$ Mn) Analysis By Region
        14.1.1. Brachytherapy Services
        14.1.2. External Beam Radiation Therapy (EBRT)
        14.1.3. Surgery
   14.2. Market Size (US$ Mn) and Forecast By Region, 2017-2025
        14.2.1. Brachytherapy Services
        14.2.2. External Beam Radiation Therapy (EBRT)
        14.2.3. Surgery

15. Global Market Analysis 2012–2016 and Forecast 2017–2025
   15.1. Market Size and Y-o-Y Growth
   15.2. Absolute $ Opportunity


List of Tables

Table 1: Drug Administration Reimbursement Rates
Table 2: Brachytherapy Reimbursement Rates
Table 3: Pipeline Analysis
Table 4: North America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Country
Table 5: North America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Treatment Type
Table 6: North America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Value (Units) Analysis 2012-2016 and Forecast 2017-2025, By Disease Indication
Table 7: North America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Distribution Channel
Table 8 : Brazil Study: Combination Therapy Drug Cost ($US)
Table 9 : Clinical Trials in Latin America
Table 10: Latin America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Country
Table 11: Latin America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Treatment Type
Table 12: Latin America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Value (Units) Analysis 2012-2016 and Forecast 2017-2025, By Disease Indication
Table 13: Latin America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Distribution Channel
Table 14: Europe Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Country
Table 15: Europe Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Treatment Type
Table 16: Europe Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Value (Units) Analysis 2012-2016 and Forecast 2017-2025, By Disease Indication
Table 17: Europe Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Distribution Channel
Table 18: APAC Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Country
Table 19: APAC Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Treatment Type
Table 20: APAC Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Value (Units) Analysis 2012-2016 and Forecast 2017-2025, By Disease Indication
Table 21: APAC Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Distribution Channel
Table 22: MEA Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Country
Table 23: MEA Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Treatment Type
Table 24: MEA Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Value (Units) Analysis 2012-2016 and Forecast 2017-2025, By Disease Indication
Table 25: MEA Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Distribution Channel
Table 26: Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size (US$ Mn) 2012–2016 and Forecast 2017-2025 By Region
Table 27: Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size (US$ Mn) 2012–2016 and Forecast 2017-2025 By Treatment
Table 28: Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size (US$ Mn) 2012–2016 and Forecast 2017-2025 By Disease Indication
Table 29: Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size (US$ Mn) 2012–2016 and Forecast 2017-2025 By Distribution Channel
Table 30: Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Service Spending
Table 31: Global Bile Duct Cancer (Cholangiocarcinoma) Service Treatment Market Size Analysis (US$ Mn) Analysis 2012-2016 and Forecast 2017-2025, By Region


List of Figures

Figure 1: Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Split By Chemotherapy (2017)
Figure 2: Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Split By Services (2017)
Figure 3: Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Split By Disease Indication (2017)
Figure 4: Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Split By Distribution Channel (2017)
Figure 5: Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Revenue Share by Region (2017 E)
Figure 6: United States Generic Drug  Approval Regulation
Figure 7: EU Centralized procedure for Generic Drug Approval Regulation
Figure 8: Mutual Recognition Procedure in Europe For Approval of Generic Drug
Figure 9: : Japan Decentralized Procedure For Approval of Generic Drug
Figure 10: North America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Value Share By Treatment Type (2017)
Figure 11: North America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Value Share By Disease Indication(2017)
Figure 12: North America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market
Figure 13: North America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Value Share By Distribution Channel(2017)
Figure 14: North America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Value Share By Country (2017)
Figure 15: North America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size Analysis, 2012–2016
Figure 16: North America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 17: North America Bile Duct Cancer (Cholangiocarcinoma) Market Share Analysis (%) By Country, 2017 & 2025 
Figure 18: North America Bile Duct Cancer (Cholangiocarcinoma) Market Y-o-Y Growth (%) By Country, 2016–2025
Figure 19: U.S. Bile Duct Cancer (Cholangiocarcinoma) Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 20: U.S. Bile Duct Cancer (Cholangiocarcinoma) Market Absolute $ Opportunity, 2017–2025
Figure 21: Canada Bile Duct Cancer (Cholangiocarcinoma) Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 22: Canada Bile Duct Cancer (Cholangiocarcinoma) Market Absolute $ Opportunity, 2017–2025
Figure 23: Liver and Intrahepatic bile duct cancer, estimated new cases and deaths in United States
Figure 24: Percent of new cases by age group in United States: Liver and Intrahepatic Bile Duct Cancer
Figure 25: Liver and Intrahepatic Bile Duct Cancer  Number of New Cases and Deaths per 100,000 People in United States
Figure 26: North America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Attractiveness Analysis, By Country
Figure 27: North America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Attractiveness Analysis, By Treatment Type
Figure 28: North America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Attractiveness Analysis, By Disease Indication
Figure 29: North America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Attractiveness Analysis, By Distribution Channel
Figure 30: Latin America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Value Share By Treatment Type (2017)
Figure 31: Latin America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Value Share By Disease Indication(2017)
Figure 32: Latin America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market
Figure 33: Latin America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Value Share By Distribution Channel(2017)
Figure 34: Latin America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Value Share By Country (2017)
Figure 35: Latin America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size Analysis, 2012–2016
Figure 36: Latin America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 37: Latin America Bile Duct Cancer (Cholangiocarcinoma) Market Share Analysis (%) By Country, 2017 & 2025 
Figure 38: Latin America Bile Duct Cancer (Cholangiocarcinoma) Market Y-o-Y Growth (%) By Country, 2016–2025
Figure 39: Brazil  Bile Duct Cancer (Cholangiocarcinoma) Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 40: Brazil Bile Duct Cancer Cholangiocarcinoma) Market Absolute $ Opportunity, 2017–2025
Figure 41: Mexico Bile Duct Cancer (Cholangiocarcinoma) Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 42: Mexico Bile Duct Cancer (Cholangiocarcinoma) Market Absolute $ Opportunity, 2017–2025
Figure 43: Rest of Latin America Bile Duct Cancer (Cholangiocarcinoma) Market Absolute $ Opportunity, 2017–2025
Figure 44: Rest of Latin America Bile Duct Cancer (Cholangiocarcinoma) Market Absolute $ Opportunity, 2017–2025
Figure 45: Brazil Study: Combination Therapy Drug Cost ($US)
Figure 46: Clinical Trials in Latin America
Figure 47: Estimated Annual Percent Change In Age-standardized Incidence From Gallbladder Cancer Registry (Latin America)
Figure 48: Latin America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Attractiveness Analysis, By Country
Figure 49: Latin America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Attractiveness Analysis, By Treatment Type
Figure 50: Latin America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Attractiveness Analysis, By Disease Indication
Figure 51: Latin America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Attractiveness Analysis, By Distribution Channel
Figure 52: Europe Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Value Share By Treatment Type (2017)
Figure 53: Europe Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Value Share By Disease Indication(2017)
Figure 54: Europe Bile Duct Cancer (Cholangiocarcinoma) Treatment Market
Figure 55: Europe Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Value Share By Distribution Channel(2017)
Figure 56: Europe Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Value Share By Country (2017)
Figure 57: Europe Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size Analysis, 2012–2016
Figure 58: Europe Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 59: Europe Bile Duct Cancer (Cholangiocarcinoma) Market Share Analysis (%) By Country, 2017 & 2025 
Figure 60: Europe Bile Duct Cancer (Cholangiocarcinoma) Market Y-o-Y Growth (%) By Country, 2016–2025
Figure 61: Germany  Bile Duct Cancer (Cholangiocarcinoma) Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 62: Germany Bile Duct Cancer Cholangiocarcinoma) Market Absolute $ Opportunity, 2017–2025
Figure 63: France Bile Duct Cancer (Cholangiocarcinoma) Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 64: France Bile Duct Cancer (Cholangiocarcinoma) Market Absolute $ Opportunity, 2017–2025
Figure 65: U.K. Bile Duct Cancer (Cholangiocarcinoma) Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 66: U.K. Bile Duct Cancer Cholangiocarcinoma) Market Absolute $ Opportunity, 2017–2025
Figure 67: Spain Bile Duct Cancer (Cholangiocarcinoma) Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 68: Spain Bile Duct Cancer (Cholangiocarcinoma) Market Absolute $ Opportunity, 2017–2025
Figure 69: Italy Bile Duct Cancer (Cholangiocarcinoma) Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 70: Italy Bile Duct Cancer Cholangiocarcinoma) Market Absolute $ Opportunity, 2017–2025
Figure 71: Benelux Bile Duct Cancer (Cholangiocarcinoma) Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 72: Benelux Bile Duct Cancer (Cholangiocarcinoma) Market Absolute $ Opportunity, 2017–2025
Figure 73: Poland Bile Duct Cancer (Cholangiocarcinoma) Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 74: Poland Bile Duct Cancer Cholangiocarcinoma) Market Absolute $ Opportunity, 2017–2025
Figure 75: Russia Bile Duct Cancer (Cholangiocarcinoma) Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 76: Russia Bile Duct Cancer (Cholangiocarcinoma) Market Absolute $ Opportunity, 2017–2025
Figure 77: Rest of Europe Bile Duct Cancer (Cholangiocarcinoma) Market Absolute $ Opportunity, 2017–2025
Figure 78: Rest of Europe Bile Duct Cancer (Cholangiocarcinoma) Market Absolute $ Opportunity, 2017–2025
Figure 79: Estimated Incidence and Mortality of Gall Bladder and Extra Hepatic Bile Duct Cancer, 2012
Figure 80: Europe Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Attractiveness Analysis, By Country
Figure 81: Europe Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Attractiveness Analysis, By Treatment Type
Figure 82: Europe Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Attractiveness Analysis, By Disease Indication
Figure 83: Europe Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Attractiveness Analysis, By Distribution Channel
Figure 84:  APAC Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Value Share By Treatment Type (2017)
Figure 85: APAC Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Value Share By Disease Indication(2017)
Figure 86: APAC Bile Duct Cancer (Cholangiocarcinoma) Treatment Market
Figure 87: APAC Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Value Share By Distribution Channel(2017)
Figure 88: APAC Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Value Share By Country (2017)
Figure 89: APAC Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size Analysis, 2012–2016
Figure 90: APAC Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 91: APAC Bile Duct Cancer (Cholangiocarcinoma) Market Share Analysis (%) By Country, 2017 & 2025 
Figure 92: APAC Bile Duct Cancer (Cholangiocarcinoma) Market Y-o-Y Growth (%) By Country, 2016–2025
Figure 93: China Bile Duct Cancer (Cholangiocarcinoma) Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 94: China Bile Duct Cancer Cholangiocarcinoma) Market Absolute $ Opportunity, 2017–2025
Figure 95: India  Bile Duct Cancer (Cholangiocarcinoma) Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 96: India Bile Duct Cancer (Cholangiocarcinoma) Market Absolute $ Opportunity, 2017–2025
Figure 97: Australia and New Zealand  Bile Duct Cancer (Cholangiocarcinoma) Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 98: Australia and New Zealand  Bile Duct Cancer (Cholangiocarcinoma) Market Absolute $ Opportunity, 2017–2025
Figure 99: ASEAN Bile Duct Cancer (Cholangiocarcinoma) Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 100: India Bile Duct Cancer (Cholangiocarcinoma) Market Absolute $ Opportunity, 2017–2025
Figure 101: Japan Bile Duct Cancer (Cholangiocarcinoma) Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 102: Japan Bile Duct Cancer (Cholangiocarcinoma) Market Absolute $ Opportunity, 2017–2025
Figure 103: Rest of Asia Pacific Bile Duct Cancer (Cholangiocarcinoma) Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 104: Rest of Asia Pacific  Bile Duct Cancer (Cholangiocarcinoma) Market Absolute $ Opportunity, 2017–2025
Figure 105: Annual Incidence of Cholangiocarcinoma per 100,000 in Asia Pacific
Figure 106: APAC Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Attractiveness Analysis, By Country
Figure 107: APAC Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Attractiveness Analysis, By Treatment Type
Figure 108: APAC Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Attractiveness Analysis, By Disease Indication
Figure 109: APAC Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Attractiveness Analysis, By Distribution Channel
Figure 110: MEA Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Value Share By Treatment Type (2017)
Figure 111: MEA Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Value Share By Disease Indication(2017)
Figure 112: MEA Bile Duct Cancer (Cholangiocarcinoma) Treatment Market
Figure 113: MEA Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Value Share By Distribution Channel(2017)
Figure 114: MEA Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Value Share By Country (2017)
Figure 115: MEA Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size Analysis, 2012–2016
Figure 116: MEA Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 117: MEA Bile Duct Cancer (Cholangiocarcinoma) Market Share Analysis (%) By Country, 2017 & 2025 
Figure 118: MEA Bile Duct Cancer (Cholangiocarcinoma) Market Y-o-Y Growth (%) By Country, 2016–2025
Figure 119: GCC Countries  Bile Duct Cancer (Cholangiocarcinoma) Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 120: GCC Countries Bile Duct Cancer (Cholangiocarcinoma) Market Absolute $ Opportunity, 2017–2025
Figure 121: India  Bile Duct Cancer (Cholangiocarcinoma) Market Value (US$ Mn) & Y-o-Y Growth (%), 2017–2025
Figure 122: South Africa Bile Duct Cancer (Cholangiocarcinoma) Market Absolute $ Opportunity, 2017–2025
Figure 123: Rest of MEA Bile Duct Cancer (Cholangiocarcinoma) Market Absolute $ Opportunity, 2017–2025
Figure 124: Rest of MEA Bile Duct Cancer (Cholangiocarcinoma) Market Absolute $ Opportunity, 2017–2025
Figure 125: Annual Incidence of Liver Cancer per 100,000 in MEA
Figure 126: MEA Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Attractiveness Analysis, By Country
Figure 127: MEA Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Attractiveness Analysis, By Treatment Type
Figure 128: MEA Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Attractiveness Analysis, By Disease Indication
Figure 129: MEA Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Attractiveness Analysis, By Distribution Channel
Figure 130: Global Bile Duct Cancer (Cholangiocarcinoma) Market Share Analysis (%) By Country, 2017 & 2025
Figure 131: Global Bile Duct Cancer (Cholangiocarcinoma) Market Y-o-Y Growth (%) By Country, 2016–2025
Figure 132: Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Attractiveness Analysis By Region, 2017–2025
Figure 133: Global Bile Duct Cancer (Cholangiocarcinoma) Market Share Analysis (%) By Country, 2017 & 2025
Figure 134: Global Bile Duct Cancer (Cholangiocarcinoma) Market Y-o-Y Growth (%) By Country, 2016–2025
Figure 135: Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Attractiveness Analysis By Treatment Type, 2017–2025
Figure 136: Global Bile Duct Cancer (Cholangiocarcinoma) Market Share Analysis (%) By Disease Indication, 2017 & 2025
Figure 137: Global Bile Duct Cancer (Cholangiocarcinoma) Market Y-o-Y Growth (%) By Disease Indication, 2016–2025
Figure 138: Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Attractiveness Analysis By Treatment Type, 2017–2025
Figure 139: Global Bile Duct Cancer (Cholangiocarcinoma) Market Share Analysis (%) By Distribution  Channel, 2017 & 2025
Figure 140: Global Bile Duct Cancer (Cholangiocarcinoma) Market Y-o-Y Growth (%) By Country, 2016–2025
Figure 141: Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Attractiveness Analysis By Distribution Channel, 2017–2025
Figure 142: Global Historical Market Size and Y-o-Y, 2012 - 2016
Figure 143: Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Absolute $ Opportunity (US$ Mn), 2017–2025
Figure 144: Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Absolute $ Opportunity, 2012–2025